Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2015

View Archived Issues

SKY92 gene expression signature combined with ISS in MM survival prognosis

Transient expression of ZSCAN4 corrects trisomy in cells from people with Down syndrome

Homozygous mutation in PPP1R15B leads to beta-cell dysfunction and diabetes

New financing round at Pharmalink to fund development of phase III program for Nefecon

Nivolumab shows enhanced overall survival in mRCC patients

Genzyme opts into Alnylam Pharmaceuticals' ALN-AT3 hemophilia program

BioCancell advances combination of BC-819 and BCG for bladder cancer

Cellectar Biosciences awarded grant to advance phospholipid drug conjugate platform

REV-002 reduces joint pain in phase IIa trial in acute gout arthritis

DeuteRx completes financing to fund clinical trials of DRX-065 for adrenoleukodystrophy

Arvinas enters license agreement with Genentech to develop therapeutics based on PROTAC technology

Celdara and Pulmatrix receive NIH grant to develop inhaled biologic for IPF

Photocure initiates phase III study of Cysview with blue light cystoscopy in surveillance setting

New approaches for the treatment of diabetes: ECM capsules and bioactive nanocoatings

Novel mitochondrial RNA mutation linked to breast cancer

IAPs show promise for the treatment of M. tuberculosis and M. avium infections

Anthera begins phase III SOLUTION study of oral Sollpura

Encore Vision starts phase I/II trial of EV-06 in presbyopia

Algiax discloses GABA(A) receptor modulators

Bristol-Myers Squibb introduces NS5B inhibitors

Yissum reports mushroom ostreolyisin compositions

Nivalis Therapeutics divulges CFTR modulators

AstraZeneca introduces ENaC modulators

Innate Pharma initiates phase I/II trial of IPH-2201 in combination with ibrutinib for CLL

FDA approves Aristada for schizophrenia

Cardinal Health completes acquisition of J&J's Cordis business

Cobimetinib increases overall survival in patients with melanoma treated with vemurafenib

Gilead's new treatment combination of Letairis and tadalafil gains FDA approval for PAH

Cell Therapy plans European CMA submission for Heartcel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...